NPCE logo

NeuroPace, Inc. Stock Price

NasdaqGM:NPCE Community·US$340.1m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

NPCE Share Price Performance

US$10.28
3.82 (59.13%)
48.6% undervalued intrinsic discount
US$20.00
Fair Value
US$10.28
3.82 (59.13%)
48.6% undervalued intrinsic discount
US$20.00
Fair Value
Price US$10.28
AnalystHighTarget US$20.00
AnalystConsensusTarget US$17.13
AnalystLowTarget US$13.00

NPCE Community Narratives

AnalystHighTarget·
Fair Value US$20 48.6% undervalued intrinsic discount

Aging Global Population And Advanced Neurostimulation Will Expand Treatment Options

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value US$17.13 40.0% undervalued intrinsic discount

Expanding Level 4 Epilepsy Centers Will Unlock Future Potential

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value US$13 20.9% undervalued intrinsic discount

Rising Regulatory Pressures Will Undermine Neurotech And Spur Cautious Optimism

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Recent NPCE News & Updates

NeuroPace, Inc. Key Details

US$88.6m

Revenue

US$21.5m

Cost of Revenue

US$67.1m

Gross Profit

US$93.0m

Other Expenses

-US$25.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.78
Gross Margin
75.74%
Net Profit Margin
-29.29%
Debt/Equity Ratio
301.6%

NeuroPace, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and good value.

0 Risks
4 Rewards

About NPCE

Founded
1997
Employees
209
CEO
Joel Becker
WebsiteView website
www.neuropace.com

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›